protein

Recombinant Human Fibroblast Growth Factorbasic

MBS197025

0.01 mg

205 USD

Recombinant Protein

Recombinant Human Fibroblast Growth Factorbasic

Fibroblast Growth Factor - basic (rHuFGF-b)

Recombinant Human Fibroblast Growth Factor - basic (rHuFGF-b)

fibroblast growth factor; Heparin-binding growth factor 2; heparin-binding growth factor 2; prostatropin; OTTHUMP00000037513; basic fibroblast growth factor bFGF; fibroblast growth factor 2 (basic); Basic fibroblast growth factor

FGF2; FGF2; BFGF; FGFB; HBGF-2; FGFB

FGF2_HUMAN

E Coli

288

Recombinant Human Fibroblast Growth Factor - basic (rHuFGF-b)

Greater than 98% by RP-HPLC, anion-exchange chromatography; reducing and non-reducing SDS-PAGE, silver stain. Purification: Chromatographic

Sterile filtered, lyophilized.

Lyophilized product is stable at room temperature for 3 weeks. Store lyophilized product desiccated at -20 degree C. Upon reconstitution, store at 4 degree C for 2-7 days or aliquot and store at -20 degree C. For long-term storage add either HSA or BSA to 0.1%. Avoid repeated freeze-thaw cycles.

Dimers/Aggregates: <1% by SDSPAGE. Biological Activity: Fully biologically active compared to reference standards. Specific Activity is 2 x 10^6 Units/mg.

Endotoxin Level: <0.1 ng/ug. Protein Content: Determined spectrophotometrically at 280nm (0.8511 ext. coeff), and by RP-HPLC analysis against a calibrated standard. Solubility: Reconstitute the lyophilized product in sterile water not less than 100 ug/ml. Product was dialyzed against 5mM Tris pH 7.5/150mM NaCl prior to lyophilization. Stabilizer: None. Preservatives: None

Recombinant Proteins

Recombinant Human FGF-basic produced in E. coli is a single, nonglycosylated polypeptide chain containing 155 amino acids with a molecular mass of 17,353 daltons. This product has full biological activity.

31362

CAA28027.1

P09038

30,770 Da

Angiopoietin Receptor Tie2-mediated Signaling Pathway 137917!!Downstream Signaling Of Activated FGFR Pathway 160957!!Endochondral Ossification Pathway 198812!!FGFR Ligand Binding And Activation Pathway 106344!!FGFR1 Ligand Binding And Activation Pathway 106345!!FGFR1b Ligand Binding And Activation Pathway 106346!!FGFR1c Ligand Binding And Activation Pathway 106347!!FGFR2 Ligand Binding And Activation Pathway 106349!!FGFR2c Ligand Binding And Activation Pathway 106351!!FGFR3 Ligand Binding And Activation Pathway 106352

The protein encoded by this gene is a member of the fibroblast growth factor (FGF) family. FGF family members bind heparin and possess broad mitogenic and angiogenic activities. This protein has been implicated in diverse biological processes, such as limb and nervous system development, wound healing, and tumor growth. The mRNA for this gene contains multiple polyadenylation sites, and is alternatively translated from non-AUG (CUG) and AUG initiation codons, resulting in five different isoforms with distinct properties. The CUG-initiated isoforms are localized in the nucleus and are responsible for the intracrine effect, whereas, the AUG-initiated form is mostly cytosolic and is responsible for the paracrine and autocrine effects of this FGF. [provided by RefSeq]

Function: The heparin-binding growth factors are angiogenic agents in vivo and are potent mitogens for a variety of cell types in vitro. There are differences in the tissue distribution and concentration of these 2 growth factors. Ref.11. Subunit structure: Monomer. Interacts with CSPG4 and FGFBP1. Found in a complex with FGFBP1, FGF1 and FGF2. Ref.20 Ref.21 Ref.22. Tissue specificity: Expressed in granulosa and cumulus cells. Expressed in hepatocellular carcinoma cells, but not in non-cancerous liver tissue. Ref.11 Ref.18. Post-translational modification: Several N-termini starting at positions 94, 125, 126, 132, 143 and 162 have been identified by direct sequencing. Miscellaneous: This protein binds heparin more strongly than does aFGF. Sequence similarities: Belongs to the heparin-binding growth factors family. Biophysicochemical propertiespH dependence:Retains almost half of its activity after treatment at pH 2.0 for 3 hours at 20 degrees Celsius. Ref.11Temperature dependence:Inactivated after 3 minutes at 60 degrees Celsius or 1 minute at 80 degrees Celsius. Sequence caution: The sequence AAA52448.1 differs from that shown. Reason: Frameshift at positions 25, 82, 98 and 133. The sequence AAB21432.2 differs from that shown. Reason: Frameshift at position 25. The sequence AAB21432.2 differs from that shown. Reason: Unusual initiator. The initiator methionine is coded by a non-canonical CTG leucine codon.The sequence ABO43041.1 differs from that shown. Reason: Erroneous initiation. Translation N-terminally extended.The sequence ABO43041.1 differs from that shown. Reason: Unusual initiator. The initiator methionine is coded by a non-canonical CTG leucine codon.The sequence CAA28027.1 differs from that shown. Reason: Frameshift at positions 25 and 102. The sequence CAA28027.1 differs from that shown. Reason: Unusual initiator. The initiator methionine is coded by a non-canonical CTG leucine codon.The sequence CAA73868.1 differs from that shown. Reason: Frameshift at position 25. The sequence CAA73868.1 differs from that shown. Reason: Unusual initiator. The initiator methionine is coded by a non-canonical CTG leucine codon.The sequence EAX05222.1 differs from that shown. Reason: Erroneous initiation. Translation N-terminally extended.The sequence EAX05222.1 differs from that shown. Reason: Unusual initiator. The initiator methionine is coded by a non-canonical CTG leucine codon.

0.01 mg

205 USD